CoChat

Tumorigenic activity and therapeutic inhibition of Rheb GTPase

Open access
Mavrakis, Konstantinos J., Zhu, Hong, Silva, Ricardo L.A., Mills, John R., Teruya-Feldstein, Julie, Lowe, Scott W., Tam, Wayne, Pelletier, Jerry, Wendel, Hans-Guido · 2008 · Genes & Development
Cited by 113

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

The AKT–mTOR pathway harbors several known and putative oncogenes and tumor suppressors. In a phenotypic screen for lymphomagenesis, we tested candidate genes acting upstream of and downstream from mTOR in vivo. We find that Rheb, a proximal activator of mTORC1, can produce rapid development of aggressive and drug-resistant lymphomas. Rheb causes mTORC1-dependent effects on apoptosis, senescence, and treatment responses that resemble those of Akt. Moreover, Rheb activity toward mTORC1 requires farnesylation and is readily blocked by a pharmacological inhibitor of farnesyltransferase (FTI). In Pten-deficient tumor cells, inhibition of Rheb by FTI is responsible for the drug’s anti-tumor effects, such that a farnesylation-independent mutant of Rheb renders these tumors resistant to FTI therapy. Notably, RHEB is highly expressed in some human lymphomas, resulting in mTORC1 activation and increased sensitivity to rapamycin and FTI. Downstream from mTOR, we examined translation initiation factors that have been implicated in transformation in vitro. Of these, only eIF4E was able to enhance lymphomagenesis in vivo. In summary, the Rheb GTPase is an oncogenic activity upstream of mTORC1 and eIF4E and a direct therapeutic target of farnesyltransferase inhibitors in cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1101/gad.1690808

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Research works printed but not linked: 45

  1. 10.1016/j.ccr.2004.05.024 · DOI · Paper page
  2. 10.1074/jbc.M503763200 · DOI · Paper page
  3. 10.1111/j.1365-2141.2008.07099.x · DOI
  4. 10.1016/j.bbrc.2006.03.220 · DOI · Paper page
  5. Burnett,, 2007, Tipifarnib in acute myeloid leukemia, Drugs Today (Barc), 43, 795, 10.1358/dot.2007.43.11.1088617 · doi:10.1358/dot.2007.43.11.1088617
  6. 10.1038/sj.onc.1207544 · DOI · Paper page
  7. Dilling,, 1994, Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor, Cancer Res., 54, 903
  8. Donze,, 1995, Abrogation of translation initiation factor eIF-2 phosphorylation causes malignant transformation of NIH 3T3 cells, EMBO J., 14, 3828, 10.1002/j.1460-2075.1995.tb00052.x · DOI · Paper page
  9. 10.1126/science.1130276 · DOI · Paper page
  10. Du,, 1999, Geranylgeranylated RhoB mediates suppression of human tumor cell growth by farnesyltransferase inhibitors, Cancer Res., 59, 5492
  11. 10.1038/sj.onc.1207738 · DOI
  12. 10.1016/0092-8674(92)90123-T · DOI · Paper page
  13. Fukuchi-Shimogori,, 1997, Malignant transformation by overproduction of translation initiation factor eIF4G, Cancer Res., 57, 5041
  14. 10.1158/1535-7163.MCT-04-0347 · DOI · Paper page
  15. 10.1101/gad.1212704 · DOI · Paper page
  16. 10.1128/MCB.00289-08 · DOI · Paper page
  17. 10.1038/sj.onc.1205792 · DOI
  18. 10.1083/jcb.jcb.200206108 · DOI · Paper page
  19. 10.1200/JCO.2004.08.082 · DOI
  20. 10.1182/blood-2006-04-014357 · DOI · Paper page
  21. 10.1158/0008-5472.CAN-07-0752 · DOI · Paper page
  22. 10.1158/1078-0432.CCR-05-0421 · DOI · Paper page
  23. 10.1038/345544a0 · DOI · Paper page
  24. 10.4161/cc.3.10.1196 · DOI · Paper page
  25. 10.1073/pnas.1332764100 · DOI · Paper page
  26. 10.1101/gad.1314405 · DOI · Paper page
  27. 10.1038/sj.onc.1207549 · DOI · Paper page
  28. 10.1371/journal.pone.0000242 · DOI · Paper page
  29. 10.1101/gad.1314605 · DOI · Paper page
  30. McCurrach,, 2001, Methods for studying pro- and antiapoptotic genes in nonimmortal cells, Methods Cell Biol., 66, 197, 10.1016/S0091-679X(01)66010-2 · DOI
  31. 10.1002/gcc.10025 · doi:10.1002/gcc.10025
  32. 10.1074/jbc.M010551200 · DOI · Paper page
  33. 10.1074/jbc.M001938200 · DOI · Paper page
  34. 10.1038/nm1042 · DOI · Paper page
  35. 10.1016/S1535-6108(02)00047-8 · DOI · Paper page
  36. Silva,, 2007, MNK, EIF4E and targeting translation for therapy, Cell Cycle, 7, 553, 10.4161/cc.7.5.5486 · DOI
  37. 10.1016/j.ccr.2006.08.022 · DOI · Paper page
  38. 10.1016/j.molcel.2007.11.018 · DOI · Paper page
  39. 10.1038/348331a0 · DOI · Paper page
  40. 10.1158/0008-5472.CAN-05-0917 · DOI · Paper page
  41. 10.1038/nrc839 · DOI · Paper page
  42. 10.1038/nature02369 · DOI · Paper page
  43. 10.1158/0008-5472.CAN-06-0419 · DOI · Paper page
  44. 10.1101/gad.1212504 · DOI
  45. 10.1261/rna.7191905 · DOI · Paper page

Cited by

See all 113

Metadata

Authors
Mavrakis, K. J., Zhu, H., Silva, R. L. A., Mills, J. R., Teruya-Feldstein, J., Lowe, S. W., Tam, W., Pelletier, J., & Wendel, H.-G.
Venue
Genes & Development
Published
2008-08-15
Volume
22
Issue
16
Pages
2178-2188
ISSN
  • 0890-9369 (ISSN-L)
  • 1549-5477
OpenAlex
W2119540996
Cited by
113
References
14
Type
posted content
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tumorigenic activity and therapeutic inhibition of Rheb GTPase. https://app.cochat.ai/papers/10.1101/gad.1690808
The paper
Mavrakis, K. J., Zhu, H., Silva, R. L. A., Mills, J. R., Teruya-Feldstein, J., Lowe, S. W., Tam, W., Pelletier, J., & Wendel, H.-G. (2008). Tumorigenic activity and therapeutic inhibition of Rheb GTPase. Genes & Development. https://doi.org/10.1101/gad.1690808

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.